B 
9.87
+3.46%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Latest on Benitec Biopharma
Our reporting
- Benitec Biopharma rises 3.46% in Monday's session
- Benitec Biopharma rises 10.42% in Friday's session
- Benitec Biopharma falls 2.86% in Monday's session
- Benitec Biopharma rises 3.76% in Thursday's session
- Benitec Biopharma falls 5.97% in Wednesday's session
- Benitec Biopharma rises 8.13% in Tuesday's session
Next results
Due on 13 Nov 2026. Analysts expect earnings of -0.27 a share.
Past results
Reported against what analysts expected
| 14 Sept 2026 | 14 May 2026 | 12 Feb 2026 | 14 Nov 2025 | 22 Sept 2025 | 14 Feb 2025 | |
|---|---|---|---|---|---|---|
| Earnings per share | -0.26 | -0.24 | -0.26 | -0.22 | -0.42 | -0.36 |
| Forecast | -0.26 | -0.27 | -0.23 | -0.35 | -0.28 | -1.00 |
| Revenue | — | — | — | — | $556,000 | — |
| Forecast | $13.7m | $4.5m | — | — | — | — |
Key events
- 26 Jul 202317-to-1 reverse split
- 15 Apr 20203-to-2 reverse split
- 18 Nov 201910-to-1 reverse split
- 16 Jun 20154-to-1 reverse split
- 30 May 2014200-for-1 share split
- 11 Jul 2012Listed
Benitec Biopharma in the news
Headlines from other publishers, linked to their own pages.
- Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD) (opens Yahoo in a new tab) Yahoo · 10 Mar 2026
- Benitec To Highlight Key Clinical Results Observed To Date For OPMD Patients Enrolled Into BB-301 Phase 1b/2a Clinical Treatment Study And Potential For BB-301 To Transform Treatment Landscape For Patients With OPMD At 2026 MDA Clinical and Scientific Conference (opens Benzinga in a new tab) Benzinga · 10 Mar 2026
- Benitec Biopharma shares are trading higher after the company announced Oculopharyngeal Muscular Dystrophy Patients treated with BB-301 experienced improvements in throat closure, throat emptying, and total dysphagic symptom burden. (opens Benzinga in a new tab) Benzinga · 9 Mar 2026
- HC Wainwright & Co. Reiterates Buy on Benitec Biopharma, Maintains $32 Price Target (opens Benzinga in a new tab) Benzinga · 9 Mar 2026
- Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference (opens Yahoo in a new tab) Yahoo · 9 Mar 2026
- Benitec Biopharma Announced Promising Interim Clinical Results From The BB-301 Phase 1b/2a First-in-human Study (NCT06185673) Evaluating Low Dose And High Dose BB-301 Treatment For Oculopharyngeal Muscular Dystrophy With Moderate Dysphagia (opens Benzinga in a new tab) Benzinga · 9 Mar 2026
- Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference (opens Yahoo in a new tab) Yahoo · 23 Feb 2026
- Benitec Biopharma BB-301 Phase 1b/2a Late-Breaking Abstract Accepted At 2026 Muscular Dystrophy Association Clinical And Scientific Conference (opens Benzinga in a new tab) Benzinga · 23 Feb 2026
Sources and methodology
- Data on this tab
- Our reporting and our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.